Aanesthetic Agents for Day Surgery - NIHR Health Technology ...
Aanesthetic Agents for Day Surgery - NIHR Health Technology ...
Aanesthetic Agents for Day Surgery - NIHR Health Technology ...
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
64<br />
Results of the adult economic evaluation<br />
TABLE 40 Comparison of the variable cost per patient from the<br />
empirical study and the simulation <strong>for</strong> the adult study<br />
Anaesthetic Mean (SD) variable cost (£)<br />
regimen<br />
Empirical study Simulation<br />
Propofol/propofol 21.1 (12.2) 21.7 (11.4)<br />
Propofol/sevoflurane 13.8 (11.7) 14.4 (8.1)<br />
Propofol/isoflurane 7.4 (4.4) 7.2 (4.0)<br />
Sevoflurane/sevoflurane 15.3 (6.8) 15.1 (5.6)<br />
groups (ANOVA, F (3,705), 5.34; p = 0.0012).<br />
The sevoflurane/sevoflurane group had a<br />
significantly lower net benefit than did the<br />
propofol/isoflurane and the propofol/<br />
propofol groups (Tukey’s HSD test,<br />
p < 0.01) (Figure 16).<br />
Figure 17 shows the cumulative percentage of the<br />
net benefit/cost <strong>for</strong> each arm. The net cost was<br />
positive <strong>for</strong> around 15–25% of patients in the<br />
four study groups.<br />
TABLE 41 The results of the simulation <strong>for</strong> the case where all groups in the adult study receive prophylactic ondansetron<br />
Anaesthetic regimen Variable cost per patient Patients with PONV ICER (£/PONV<br />
(95% CI) (£) (95% CI) (%) instance avoided)<br />
Propofol/propofol 25.5 (24.7 to 26.3) 9.4 (6.4 to 12.4) 289 *<br />
Propofol/sevoflurane 17.7 (17.2 to 18.3) 12.1 (8.2 to 16.1) 3350 †<br />
Propofol/isoflurane 11.0 (10.7 to 11.2) 12.3 (8.2 to 16.4) –<br />
Sevoflurane/sevoflurane 18.9 (18.5 to 19.3) 20.3 (14.7 to 26.0) Dominated<br />
* Calculated with respect to the propofol/sevoflurane regimen<br />
† Calculated with respect to the propofol/isoflurane regimen<br />
TABLE 42 The results of the simulation <strong>for</strong> the case where all groups in the adult study except the propofol/propofol group receive<br />
prophylactic ondansetron<br />
Anaesthetic regimen Variable cost per patient Patients with PONV ICER (£/PONV<br />
(95% CI) (£) (95% CI) (%) instance avoided) *<br />
Propofol/propofol 21.1 13.9 (9.8 to 18.1) Dominated<br />
Propofol/sevoflurane 17.7 (17.2 to 18.3) 12.1 (8.2 to 16.1) 3350<br />
Propofol/isoflurane 11.0 (10.7 to 11.2) 12.3 (8.2 to 16.4) –<br />
Sevoflurane/sevoflurane 18.9 (18.5 to 19.3) 20.3 (14.7 to 26.0) Dominated<br />
* Calculated with respect to the propofol/isoflurane regimen<br />
TABLE 43 Net cost (£) by anaesthetic regimen in the adult study (invalid answers excluded)<br />
Net cost Anaesthetic regimen Total<br />
(n = 709)<br />
Propofol/ Propofol/ Propofol/ Sevoflurane/<br />
propofol isoflurane sevoflurane sevoflurane<br />
(n = 178) (n = 189) (n = 182) (n = 162)<br />
Mean (SD) total cost (£) 131.4 (88.9) 116.8 (79.8) 129.9 (99.3) 128.3 (72.8) 126.5 (85.8)<br />
Mean (SD) net benefit 50.8 (286.1) 106.6 (245.4) 38.7 (209.4) –23.3 (151.5) 45.6 (343.1)<br />
(induction only, Net[I])<br />
Mean (SD) net benefit 324.5 (526.5) 265.8 (333.2) 271.3 (401.8) 185.1 (343.6) 263.0 (410.4)<br />
(maintenance only, Net[M])<br />
Mean (SD) net benefit 507.3 (640.6) 489.1 (631.8) 440.8 (499.2) 289.0 (395.5) 435.5 (560.1)<br />
(induction and maintenance,<br />
Net[I + M])